SCIENCE@home

Elevation of serum N-glycolylneuraminic acid glycoconjugates in colorectal cancer.

Xavier De Bisscop,L. Shewell,Christopher J Day,Michael P. Jennings

Published 2026 in Biochemical and Biophysical Research Communications - BBRC

ABSTRACT

Colorectal cancer (CRC) is the third most common cancer globally and a major contributor to cancer-related mortality. Implementation of screening programs in average-risk populations have reduced CRC-related mortality, despite the suboptimal sensitivity of currently used techniques. Novel screening methods with improved accuracy would be expected to further reduce CRC mortality. We previously developed a surface plasmon resonance-based assay that utilizes a N-glycolyl neuraminic acid (Neu5Gc)-specific lectin, SubB2M, to measure levels of Neu5Gc glycoconjugate cancer biomarkers in human serum. In this study, Neu5Gc glycoconjugate levels were measured in the serum of colorectal cancer patients (n = 96) and compared to cancer-free controls (n = 24). A significant increase in serum Neu5Gc levels was observed in patients at every stage of colorectal cancer when compared to the cancer-free control group (P ≤ 0.001). Receiver operating characteristic analysis of these data showed that the assay could distinguish colorectal cancer cases from healthy controls with a sensitivity of 93.75% and specificity of 79.17% and had an AUC of 0.8529. These findings reveal a correlation between serum Neu5Gc and colorectal cancer and highlight the potential for Neu5Gc glycoconjugates to be used as a serum biomarker for colorectal cancer.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-39 of 39 references · Page 1 of 1

CITED BY

  • No citing papers are available for this paper.

Showing 0-0 of 0 citing papers · Page 1 of 1